Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· April 14, 2026

NeuroTrader Launches AI Crypto Trading Platform With Free Entry and Five Subscription Tiers

View original at globenewswire.com
NeuroTrader Launches AI Crypto Trading Platform With Free Entry and Five Subscription Tiers DELRAY BEACH, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- NeuroTrader, a multi-AI decision intelligence system built on ensemble consensus, officially opens to the public with five subscription tiers starting at $0 per month…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Performance data will accumulate as the live environment scales

    60% confidence

  • Ensemble consensus architecture is designed to filter out the noise that causes single-model AI crypto bots to overtrade or misread market conditions

    60% confidence

  • NeuroTrader runs six independent intelligence engines in parallel and only executes a trade when multiple engines reach weighted agreement

    60% confidence

  • User funds never leave the exchange. API keys carry zero withdrawal permissions, are encrypted at rest with AES-256, and isolated per user

    60% confidence

  • NeuroTrader is not projecting guaranteed returns and the system is in its early activation phase

    60% confidence

  • Phase 3 Adaptive Intelligence Core is where the system shifts from executing predefined logic to evolving through its own performance data

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com